MedTrace Logo

Adverse Plaque Characteristics in CCTA and TVC Imaging

NCT02350959 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-10-07

No results posted yet for this study

Summary

The present study is intended to assess the vulnerability of plaques seen on CCTA by means of TVC Imaging System and to make comparisons between plaques with adverse plaque characteristics and ones without adverse plaque characteristics in terms of plaque volume and lipid core contents.

Conditions

  • Plaque

Interventions

DRUG

Atorvastatin

in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography

DRUG

Atorvastatin

in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography

Sponsors & Collaborators

  • National Health Insurance Service Ilsan Hospital

    lead OTHER

Principal Investigators

  • Sanghoon Shin, M.D. · National Health Insurance Service Ilsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-01-31
Completion
2017-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02350959 on ClinicalTrials.gov